Thus, the biomarkers that have received clinical attention for AD diagnosis are Aβ, total-tau (T-tau) and phosphorylated-tau (P-tau), as they are recognized by the International Working Group (IWG) 2 Criteria for AD and the National Institute on Aging-Alzheimer’s Association (NIA-AA) Criteria for AD and MCI associated with AD [35,39]. This evidence concerns the gene MAPT and Alzheimer disease.